drugset / Trial / NCT00693004

Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease

NCT00693004

Phase 2 Terminated 236 enrolled Epix Pharmaceuticals, Inc.
Treatment

Summary

A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 monotherapy in subjects with Alzheimer's disease. The study consists of a 3-month double-blind treatment period and an optional 3-month extension period.

Timeline

Start
2008-05
Primary completion
2010-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule
Subject PRX-03140 Small molecule

Indications